- Home
- SLG vs TARS Comparison
SLG vs TARS Comparison
Compare SLG & TARS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SLG | TARS |
|---|---|---|
| Founded | 1980 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Medicinal Chemicals and Botanical Products |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.0B | 2.8B |
| IPO Year | 1997 | 2020 |
Fundamental Metrics
Financial Performance| Metric | SLG | TARS |
|---|---|---|
| Price | $44.61 | $81.80 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 17 | 9 |
| Target Price | $59.12 | ★ $76.56 |
| AVG Volume (30 Days) | ★ 1.5M | 419.7K |
| Earning Date | 01-21-2026 | 11-04-2025 |
| Dividend Yield | ★ 6.92% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $661,814,000.00 | $366,100,000.00 |
| Revenue This Year | N/A | $147.24 |
| Revenue Next Year | $9.94 | $53.11 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 182.44 |
| 52 Week Low | $40.26 | $38.51 |
| 52 Week High | $76.49 | $85.25 |
Technical Indicators
Market Signals| Indicator | SLG | TARS |
|---|---|---|
| Relative Strength Index (RSI) | 42.83 | 62.74 |
| Support Level | $40.26 | $78.10 |
| Resistance Level | $45.39 | $85.25 |
| Average True Range (ATR) | 1.78 | 3.08 |
| MACD | 0.24 | -0.28 |
| Stochastic Oscillator | 56.13 | 55.70 |
Price Performance
Historical ComparisonAbout SLG SL Green Realty Corp
SL Green Realty is one of the largest Manhattan property owners and landlords, with interest in around 32 million square feet of wholly owned and joint-venture office space. The company has additional property exposure through its limited portfolio of well-located retail space. It operates as a real estate investment trust.
About TARS Tarsus Pharmaceuticals Inc.
Tarsus Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of therapeutics, starting with eye care. The company is focused on the development and commercialization of first-in-class therapeutic candidates to provide treatment for ophthalmic conditions. The company's candidate XDEMVY is a novel investigational eye drop to treat blepharitis caused by the infestation of Demodex mites, referred to as Demodex blepharitis.